The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Reduced levels of NR2A and NR2B subunits of NMDA receptor and PSD-95 in the prefrontal cortex in major depression
Open accessAbstract
Recent neuroimaging and postmortem studies have demonstrated abnormalities in glutamatergic transmission in major depression. Glutamate NMDA (N-methyl-d-aspartate) receptors are one of the major mediators of excitatory neurotransmission in the central nervous system. At synaptic sites, NMDA receptors are linked with postsynaptic density protein-95 (PSD-95) that plays a key role in mediating trafficking, clustering, and downstream signaling events, following receptor activation. In this study, we examined the expression of NMDA receptor subunits NR1, NR2A, and NR2B as well as PSD-95 in the anterior prefrontal cortex (PFC) using Western blot method. Cortical samples were obtained from age, gender and postmortem interval matched depressed and psychiatrically healthy controls. The results revealed that there was a reduced expression of the NMDA receptor subunits NR2A (-54%) and NR2B (-48%), and PSD-95 protein level (-40%) in the PFC of depressed subjects relative to controls, with no change in the NR1 subunit. The alterations in NMDA receptor subunits, especially the NR2A and NR2B, as well as PSD-95 suggest an abnormality in the NMDA receptor signaling in the PFC in major depression. Our findings in conjunction with recent clinical, cellular, and neuroimaging studies further implicate the involvement of glutamate neurotransmission in the pathophysiology of depression. This study provides additional evidence that NMDA receptor complex is a target for discovery of novel antidepressants.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Evidence in support of a reduction of synapse number is provided by reports of decreased levels of synaptic signaling proteins in MDD patients, including decreased levels of glutamate receptor subtypes, presynaptic neurotransmitter vesicle-associated proteins, and postsynaptic structural and functional proteins in the dlPFC, the hippocampus, and other forebrain structures (16–19).”
From Synaptic Dysfunction in Depression: Potential Therapeutic Targets (2012) · cites this paper as [18]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Postmortem studies have demonstrated that patients with depression and related mental illnesses have lower BDNF and/or TRKB mRNA levels (75–77), reduced cortical neuron size (75, 78, 79), lower synaptic protein levels (80), decreased mTOR signaling (81), and fewer dendritic spines/synapses (82, 83) in the PFC.”
From Psychedelics and Other Psychoplastogens for Treating Mental Illness. (2021) · cites this paper as [80]
In the citing paper
“Protein expression levels of the NMDA subunits NR2A/NR2B and PSD95 are also reduced in PFC of MDD patients 210”
From Mechanisms of synaptic transmission dysregulation in the prefrontal cortex: pathophysiological implications (2022) · cites this paper as [210]
In the citing paper
“It is interesting to note that the expression and function of mTORC1 signaling proteins is reduced in postmortem PFC of depressed subjects, which could contribute to decreased synthesis of synaptic proteins in PFC of depressed subjects50,51.”
From Synaptic plasticity and depression: new insights from stress and rapid-acting antidepressants (2016) · cites this paper as [50]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Antidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766
Monyer, H., Burnashev, N., Laurie, D. J., Sakmann, B., & Seeburg, P. H. (1994) · Neuron · doi:10.1016/0896-6273(94)90210-0 · Cited by 3,535
Domain Interaction Between NMDA Receptor Subunits and the Postsynaptic Density Protein PSD-95
Kornau, H., Schenker, L. T., Kennedy, M. B., & Seeburg, P. H. (1995) · Science · doi:10.1126/science.7569905 · Cited by 1,916
Moghaddam, B., Adams, B., Verma, A., & Daly, D. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-08-02921.1997 · Cited by 1,793
Extrasynaptic NMDARs oppose synaptic NMDARs by triggering CREB shut-off and cell death pathways
Hardingham, G. E., Fukunaga, Y., & Bading, H. (2002) · Nature Neuroscience · doi:10.1038/nn835 · Cited by 1,686
Rajkowska, G., Miguel-Hidalgo, J. J., Wei, J., Dilley, G., Pittman, S. D., Meltzer, H. Y., Overholser, J. C., Roth, B. L., & Stockmeier, C. A. (1999) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00041-4 · Cited by 1,477
Self-citationAnterior prefrontal cortex: insights into function from anatomy and neuroimaging
Ramnani, N., & Owen, A. M. (2004) · Nature Reviews Neuroscience · doi:10.1038/nrn1343 · Cited by 1,170
Maeng, S., Zarate, C. A., Du, J., Schloesser, R. J., McCammon, J., Chen, G., & Manji, H. K. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.05.028 · Cited by 1,103
Hasler, G., van der Veen, J. W., Tumonis, T., Meyers, N., Shen, J., & Drevets, W. C. (2007) · Archives of General Psychiatry · doi:10.1001/archpsyc.64.2.193 · Cited by 846
Flagged first, then by citations
Cited by
Sorted by citations
Items 101–200 of 422
Luoni, A., Macchi, F., Papp, M., Molteni, R., & Riva, M. A. (2015) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyu061 · Cited by 72
Glutamatergic Modulators for Major Depression from Theory to Clinical Use
McIntyre, R. S., & Jain, R. (2024) · CNS Drugs · doi:10.1007/s40263-024-01114-y · Cited by 69
The glycine site of NMDA receptors: A target for cognitive enhancement in psychiatric disorders
Peyrovian, B., Rosenblat, J. D., Pan, Z., Iacobucci, M., Brietzke, E. M., & McIntyre, R. S. (2019) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2019.02.001 · Cited by 76
Kaut, O., Schmitt, I., Hofmann, A., Hoffmann, P., Schlaepfer, T. E., Wüllner, U., & Hurlemann, R. (2015) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-014-0572-y · Cited by 68
Orientin improves depression‐like behavior and BDNF in chronic stressed mice
Liu, Y., Lan, N., Ren, J., Wu, Y., Wang, S., Huang, X., & Yu, Y. (2015) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.201400753 · Cited by 69
Millard, S. J., Weston-Green, K., & Newell, K. A. (2020) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2020.109908 · Cited by 62
Antidepressant mechanism of ketamine: perspective from preclinical studies
Scheuing, L., Chiu, C., Liao, H., & Chuang, D. (2015) · Frontiers in Neuroscience · doi:10.3389/fnins.2015.00249 · Cited by 66
Agmatine produces antidepressant-like effects by activating AMPA receptors and mTOR signaling
Neis, V. B., Moretti, M., Bettio, L. E. B., Ribeiro, C. M., da Rosa, P. B., Gonçalves, F. M., Lopes, M. W., Leal, R. B., & Rodrigues, A. L. S. (2016) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2016.03.009 · Cited by 67
Marsden, W. N. (2011) · Medical Hypotheses · doi:10.1016/j.mehy.2011.06.021 · Cited by 64
Sun, H., Jia, N., Guan, L., Su, Q., Wang, D., Li, H., & Zhu, Z. (2013) · Behavioural Brain Research · doi:10.1016/j.bbr.2013.08.044 · Cited by 64
Glutamate transporters: A key piece in the glutamate puzzle of major depressive disorder
Medina, A. M., Burke, S., Thompson, R. C., Bunney, W. E., Myers, R., Schatzberg, A. F., Akil, H., & Watson, S. J. (2013) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2013.04.007 · Cited by 67
Lesage, A., & Steckler, T. (2010) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2009.12.043 · Cited by 63
Pytka, K., Dziubina, A., Młyniec, K., Dziedziczak, A., Żmudzka, E., Furgała, A., Olczyk, A., Sapa, J., & Filipek, B. (2015) · Pharmacological Reports · doi:10.1016/j.pharep.2015.10.006 · Cited by 63
Cash, R. F. H., Cocchi, L., Anderson, R., Rogachov, A., Kucyi, A., Barnett, A. J., Zalesky, A., & Fitzgerald, P. B. (2019) · Human Brain Mapping · doi:10.1002/hbm.24725 · Cited by 68
Abdallah, C. G., Niciu, M. J., Fenton, L. R., Fasula, M. K., Jiang, L., Black, A. C., Rothman, D. L., Mason, G. F., & Sanacora, G. (2014) · Psychotherapy and Psychosomatics · doi:10.1159/000361078 · Cited by 61
Martín‐Hernández, D., Tendilla‐Beltrán, H., Madrigal, J. L. M., García‐Bueno, B., Leza, J. C., & Caso, J. R. (2018) · Molecular Neurobiology · doi:10.1007/s12035-018-1096-7 · Cited by 64
Goswami, D. B., Jernigan, C. S., Chandran, A., Iyo, A. H., May, W. L., Austin, M. C., Stockmeier, C. A., & Karolewicz, B. (2012) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2012.12.010 · Cited by 58
Self-citationDecreased NOS1 Expression in the Anterior Cingulate Cortex in Depression
Gao, S., Qi, X., Zhao, J., Balesar, R. A., Bao, A., & Swaab, D. F. (2012) · Cerebral Cortex · doi:10.1093/cercor/bhs285 · Cited by 59
Yang, L., Liu, J., Liu, X., Su, C., Zhang, Q., Wang, Z.-H., Cao, L.-F., Guo, X., Huang, Y., Luo, W., et al. (2019) · Neuroscience Bulletin · doi:10.1007/s12264-019-00367-8 · Cited by 59
Lv, S., Yao, K., Zhang, Y., & Zhu, S. (2022) · Neuropharmacology · doi:10.1016/j.neuropharm.2022.109378 · Cited by 60
Poleszak, E., Właź, P., Szewczyk, B., Właź, A., Kasperek, R., Wróbel, A., & Nowak, G. (2011) · Journal of Neural Transmission · doi:10.1007/s00702-011-0630-9 · Cited by 59
Pochwat, B., Sowa-Kućma, M., Kotarska, K., Misztak, P., Nowak, G., & Szewczyk, B. (2014) · Psychopharmacology · doi:10.1007/s00213-014-3671-6 · Cited by 55
Schilström, B., Konradsson‐Geuken, Å., Ivanov, V., Gertow, J., Feltmann, K., Marcus, M. M., Jardemark, K. E., & Svensson, T. H. (2010) · Synapse · doi:10.1002/syn.20853 · Cited by 56
Yang, K., Wang, C., & Sun, T. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00528 · Cited by 55
Sun, H., Guan, L., Zhu, Z., & Li, H. (2013) · PLoS ONE · doi:10.1371/journal.pone.0081775 · Cited by 55
The long noncoding RNA FEDORA is a cell type– and sex-specific regulator of depression
Issler, O., van der Zee, Y. Y., Ramakrishnan, A., Xia, S.-H., Zinsmaier, A. K., Tan, C., Li, W., Browne, C. J., Walker, D. M., Salery, M., et al. (2022) · Science Advances · doi:10.1126/sciadv.abn9494 · Cited by 51
Oh, J., Kim, Y.-K., Kim, S., Lee, B., Jang, J., Kwon, S., & Park, H. (2018) · Scientific Reports · doi:10.1038/s41598-018-30337-5 · Cited by 52
Ladagu, A. D., Olopade, F. E., Adejare, A., & Olopade, J. O. (2023) · Pharmaceuticals · doi:10.3390/ph16111535 · Cited by 55
Zinc deficiency in rats is associated with up-regulation of hippocampal NMDA receptor
Doboszewska, U., Sowa-Kućma, M., Młyniec, K., Pochwat, B., Hołuj, M., Ostachowicz, B., Pilc, A., Nowak, G., & Szewczyk, B. (2014) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2014.09.013 · Cited by 52
Eskelund, A., Li, Y., Budac, D. P., Müller, H. K., Gulinello, M. E., Sánchez, C., & Wegener, G. (2017) · Journal of Neurochemistry · doi:10.1111/jnc.14043 · Cited by 53
Rapid-Acting Antidepressants: Mechanistic Insights and Future Directions
Gerhard, D. M., & Duman, R. S. (2018) · Current Behavioral Neuroscience Reports · doi:10.1007/s40473-018-0139-8 · Cited by 52
Schizophrenia and depression, two poles of endocannabinoid system deregulation
Rodríguez-Muñoz, M., Sánchez‐Blázquez, P., Callado, L. F., Meana, J. J., & Garzón-Niño, J. (2017) · Translational Psychiatry · doi:10.1038/s41398-017-0029-y · Cited by 52
Miguel-Hidalgo, J. J., Moulana, M., Deloach, P. H., & Rajkowska, G. (2018) · Chronic Stress · doi:10.1177/2470547018814186 · Cited by 51
The dose makes the poison: From glutamate-mediated neurogenesis to neuronal atrophy and depression
Rubio-Casillas, A., & Fernández-Guasti, A. (2016) · Reviews in the Neurosciences · doi:10.1515/revneuro-2015-0066 · Cited by 49
Investigational NMDA receptor modulators for depression
Szewczyk, B., Pałucha-Poniewiera, A., Poleszak, E., Pilc, A., & Nowak, G. (2011) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2012.638916 · Cited by 50
Mechanisms of action and clinical efficacy of NMDA receptor modulators in mood disorders
Ghasemi, M., Phillips, C., Fahimi, A., McNerney, M. W., & Salehi, A. (2017) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2017.07.002 · Cited by 53
Mishra, S. K., Hidau, M. K., & Rai, S. (2020) · Neurochemistry International · doi:10.1016/j.neuint.2020.104932 · Cited by 49
Zuo, C., Cao, H., Ding, F., Zhao, J., Huang, Y., Guo, L., Huang, S., Jiang, H., Jiang, Y., & Wang, F. (2020) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2020.03.018 · Cited by 51
Gao, M., Wu, Y. J., Yang, L., Chen, F., Li, L., Li, Q., Wang, Y., Li, L., Peng, M., Yan, Y., et al. (2022) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2022.115832 · Cited by 46
Lee, C. J., Wu, H.-F., Chu, M.-C., Chung, Y.-J., Mao, W.-C., Li, C., & Lin, H. (2020) · Cerebral Cortex · doi:10.1093/cercor/bhaa244 · Cited by 43
Ketamine and suicidal ideation in depression: Jumping the gun?
Rajkumar, R., Fam, J., Yeo, E. Y. M., & Dawe, G. S. (2015) · Pharmacological Research · doi:10.1016/j.phrs.2015.05.003 · Cited by 43
Camargo, A., Pazini, F. L., Rosa, J. M., Wolin, I. A. V., Moretti, M., da Rosa, P. B., Neis, V. B., & Rodrigues, A. L. S. (2019) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2019.05.017 · Cited by 44
Marchisella, F., Creutzberg, K. C., Begni, V., Sanson, A., Wearick‐Silva, L. E., Tractenberg, S. G., Orso, R., Kestering-Ferreira, É., Grassi‐Oliveira, R., & Riva, M. A. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.653384 · Cited by 50
Björkholm, C., Jardemark, K., Schilström, B., & Svensson, T. H. (2015) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2015.07.002 · Cited by 42
Amidfar, M., Réus, G. Z., Quevedo, J., & Kim, Y.-K. (2018) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2018.03.023 · Cited by 43
Lee, Y., & Goto, Y. (2011) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2011.07750.x · Cited by 43
Zhu, K. Y., Duan, X., Cheng, X., Cheng, X., Xu, S. L., Zhang, L., Liu, P., Su, S., Duan, J., Dong, T. T.-X., et al. (2016) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2016.09.037 · Cited by 43
Modulation of behavior by scaffolding proteins of the post-synaptic density
Gao, C., Tronson, N. C., & Radulović, J. (2013) · Neurobiology of Learning and Memory · doi:10.1016/j.nlm.2013.04.014 · Cited by 41
Biomarkers of Major Depressive Disorder: Knowing is Half the Battle
Malik, S., Singh, R., Arora, G., Dangol, A., & Goyal, S. (2021) · Clinical Psychopharmacology and Neuroscience · doi:10.9758/cpn.2021.19.1.12 · Cited by 45
Jett, J. D., & Morilak, D. A. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2012.216 · Cited by 41
Microglial‐Biomimetic Memantine‐Loaded Polydopamine Nanomedicines for Alleviating Depression
Jiang, C., Yang, X., Huang, Q., Lei, T., Luo, H., Wu, D., Yang, Z., Xu, Y., Dou, Y., Ma, X., et al. (2025) · Advanced Materials · doi:10.1002/adma.202417869 · Cited by 48
Gibbons, A. S., Brooks, L., Scarr, E., & Dean, B. (2011) · Journal of Affective Disorders · doi:10.1016/j.jad.2011.10.001 · Cited by 41
Yang, L., Liu, C., Li, W., Ma, Y., Huo, S., Ozathaley, A., Ren, J., Yuan, W., Ni, H., Li, D., et al. (2021) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2021.06.015 · Cited by 42
Synaptic Abnormalities in the Infralimbic Cortex of a Model of Congenital Depression
Seese, R. R., Chen, L. Y., Cox, C. D., Schulz, D., Babayan, A. H., Bunney, W. E., Henn, F. A., Gall, C. M., & LYNCH, G. S. (2013) · Journal of Neuroscience · doi:10.1523/jneurosci.2434-13.2013 · Cited by 39
Glutamatergic NMDA Receptor as Therapeutic Target for Depression
Réus, G. Z., Abelaira, H. M., Tuon, T., Titus, S. E., Ignácio, Z. M., Rodrigues, A. L. S., & Quevedo, J. (2015) · Advances in protein chemistry and structural biology · doi:10.1016/bs.apcsb.2015.10.003 · Cited by 43
Parkinson’s disease-linked Parkin mutations impair glutamatergic signaling in hippocampal neurons
Zhu, M. J., Cortese, G. P., & Waites, C. L. (2018) · BMC Biology · doi:10.1186/s12915-018-0567-7 · Cited by 43
Zhao, J., Liu, X., Chang, D., Zhang, X., Lian, H., Du, X., & Gao, L. (2020) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.9b00669 · Cited by 42
Zinc transporters protein level in postmortem brain of depressed subjects and suicide victims
Rafało-Ulińska, A., Piotrowska, J., Kryczyk‐Poprawa, A., Opoka, W., Sowa-Kućma, M., Misztak, P., Rajkowska, G., Stockmeier, C. A., Datka, W., Nowak, G., et al. (2016) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2016.09.008 · Cited by 39
Self-citationPazini, F. L., Rosa, J. M., Camargo, A., Fraga, D. B., Moretti, M., Siteneski, A., & Rodrigues, A. L. S. (2020) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2020.109281 · Cited by 39
Sun, Y., Cheng, X., Zhang, L., Hu, J. H., chen, Y., Zhan, L., & Gao, Z. (2016) · Molecular Neurobiology · doi:10.1007/s12035-016-9715-7 · Cited by 39
Iyo, A. H., Feyissa, A. M., Chandran, A., Austin, M. C., Regunathan, S., & Karolewicz, B. (2010) · Neuroscience · doi:10.1016/j.neuroscience.2010.06.023 · Cited by 37
Self-citationGlial degeneration as a model of depression
Śmiałowska, M., Szewczyk, B., Woźniak, M., Wawrzak-Wleciał, A., & Domin, H. (2013) · Pharmacological Reports · doi:10.1016/s1734-1140(13)71518-4 · Cited by 39
Ketamine as Antidepressant? Current State and Future Perspectives
Hasselmann, H. (2013) · Current Neuropharmacology · doi:10.2174/1570159x113119990043 · Cited by 37
Fragale, J. E. C., Khariv, V., Gregor, D. M., Smith, I. M., Jiao, X., Elkabes, S., Servatius, R. J., Pang, K. C. H., & Beck, K. D. (2015) · Experimental Neurology · doi:10.1016/j.expneurol.2015.11.002 · Cited by 39
Millard, S. J., Lum, J. S., Fernandez, F., Weston–Green, K., & Newell, K. A. (2019) · Journal of Psychopharmacology · doi:10.1177/0269881118822141 · Cited by 39
Gruenbaum, B. F., Zlotnik, A. A., Frenkel, A., Fleidervish, I. A., & Boyko, M. (2022) · Metabolites · doi:10.3390/metabo12050459 · Cited by 36
Seillier, C., Lesept, F., Toutirais, O., Potzeha, F., Blanc, M., & Vivien, D. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231810336 · Cited by 47
Leung, E., Lau, E. W., Liang, A., de Dios, C., Suchting, R., Östlundh, L., Masdeu, J. C., Fujita, M., Sanches, M., Soares, J. C., et al. (2022) · Molecular Psychiatry · doi:10.1038/s41380-021-01410-9 · Cited by 33
Implication of NMDA-NO pathway in the antidepressant-like effect of ellagic acid in male mice
Lorigooini, Z., Salimi, N., Soltani, A., & Amini-Khoei, H. (2019) · Neuropeptides · doi:10.1016/j.npep.2019.04.003 · Cited by 35
Amidfar, M., Réus, G. Z., Quevedo, J., Kim, Y., & Arbabi, M. (2016) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2016.11.003 · Cited by 34
Yan, W., Liu, J.-F., Han, Y., Zhang, W., Luo, Y.-X., Xue, Y.-X., Zhu, W.-L., Yang, C., Chen, W.-H., Guo, H. L., et al. (2017) · Molecular Psychiatry · doi:10.1038/mp.2017.219 · Cited by 36
Fraga, D. B., Camargo, A., Olescowicz, G., Padilha, D. A., Mina, F., Budni, J., Brocardo, P. S., & Rodrigues, A. L. S. (2021) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2021.109476 · Cited by 35
Min, S., Luo, J., Cao, J., Wang, B., Li, P., Dong, J., Liu, Y., & Wei, K. (2014) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s67108 · Cited by 34
Eid, R. S., Lieblich, S. E., Duarte‐Guterman, P., Chaiton, J. A., Mah, A., Wong, S. J., Wen, Y., & Galea, L. A. M. (2019) · Hormones and Behavior · doi:10.1016/j.yhbeh.2019.104651 · Cited by 34
Rapid antidepressant effects: moving right along
Martinowich, K., Jimenez, D. V., Zarate, C. A., & Manji, H. K. (2013) · Molecular Psychiatry · doi:10.1038/mp.2013.55 · Cited by 34
Kiselycznyk, C., Svenningsson, P., Delpire, E. J., & Holmes, A. (2011) · Neuroscience · doi:10.1016/j.neuroscience.2011.06.015 · Cited by 33
Amat-Foraster, M., Jensen, A. A., Plath, N., Herrik, K. F., Celada, P., & Artigas, F. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.04.022 · Cited by 34
Deng, C.-K., Mu, Z., Miao, Y.-H., Liu, Y., Zhou, L., Huang, Y., Zhang, F., Wang, Y.-Y., Yang, Z.-H., Qian, Z., et al. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.01239 · Cited by 32
Pothula, S., Liu, R.-J., Wu, M., Sliby, A., Picciotto, M. R., Banerjee, P., & Duman, R. S. (2020) · Neuropsychopharmacology · doi:10.1038/s41386-020-00882-7 · Cited by 32
Kim, H. R., Lee, Y.-J., Kim, T.-W., Lim, R.-N., Hwang, D. Y., Moffat, J. J., Kim, S., Seo, J., & Ka, M. (2020) · BMC Complementary Medicine and Therapies · doi:10.1186/s12906-020-03121-0 · Cited by 36
Honokiol improves depression-like behaviors in rats by HIF-1α- VEGF signaling pathway activation
Fan, X., Sun, W., Li, Y., Tang, Q., Li, L., Yu, X. L., Wang, S., Fan, A., Xu, X., & Hong-sheng, C. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.968124 · Cited by 32
Russo, E., Leo, A., Crupi, R., Aiello, R., Lippiello, P., Spiga, R., Chimirri, S., Citraro, R., Cuzzocrea, S., Constanti, A., et al. (2016) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2016.03.008 · Cited by 29
Intrinsic Connectivity Networks of Glutamate-Mediated Antidepressant Response: A Neuroimaging Review
Demchenko, I., Tassone, V. K., Kennedy, S. H., Dunlop, K., & Bhat, V. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.864902 · Cited by 29
“Behind these changes, a variety of molecular processes related to glutamate cycling and release may be implicated, including the decreased expression NMDA-Rs (39–41), AMPARs (41, 42), or mGluRs (43), which have been reported both in humans and animal models of depression, as well as in postmortem brains of suicide vic…”
BackgroundEmerging drugs for major depressive disorder
Kennedy, S. H., & Rizvi, S. J. (2009) · Expert Opinion on Emerging Drugs · doi:10.1517/14728210903107751 · Cited by 35
Okada, M., Kawano, Y., Fukuyama, K., Motomura, E., & Shiroyama, T. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21217951 · Cited by 32
Jiang, C., Zhou, T. G., Chen, W., Lin, D., Guo, A., Liu, Z., & Fei, E. (2020) · Biology · doi:10.3390/biology9110359 · Cited by 33
Targeting NMDA Receptors in Emotional Disorders: Their Role in Neuroprotection
Wang, S., Bian, L.-H., Yin, Y., & Guo, J. (2022) · Brain Sciences · doi:10.3390/brainsci12101329 · Cited by 33
Lou, J.-S., Li, C., Yang, X., Fang, J., Yang, Y., & Guo, J. (2010) · Pharmaceutical Biology · doi:10.3109/13880201003789440 · Cited by 30
Benefits of animal models to understand the pathophysiology of depressive disorders
Czéh, B., & Simon, M. (2020) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2020.110049 · Cited by 30
Sun, Z., Jia, L., Shi, D., He, Y., Ren, Y., Yang, J., & Ma, X. (2021) · Behavioural Brain Research · doi:10.1016/j.bbr.2021.113709 · Cited by 33
Bernardo, A. M., Lee, P., Marcotte, M. D., Mian, M. Y., Rezvanian, S., Sharmin, D., Kovačević, A., Savić, M. M., Cook, J. M., Sibille, E. L., et al. (2022) · Neuropsychopharmacology · doi:10.1038/s41386-022-01360-y · Cited by 30
Zhou, M., Liu, Z., Yu, J. H., Li, S., Tang, M., Zeng, L., Wang, H., Xie, H., Peng, L., Huang, H., et al. (2018) · Neuroscience · doi:10.1016/j.neuroscience.2018.02.010 · Cited by 28
Michaëlsson, H., Andersson, M., Svensson, J., Karlsson, L., Ehn, J., Culley, G. R., Engström, A., Bergström, N., Savvidi, P., Kuhn, H. G., et al. (2018) · Acta Physiologica · doi:10.1111/apha.13211 · Cited by 31
Huang, H., Liao, H.-Y., & Lin, Y. (2020) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2020/4951591 · Cited by 30
Fogaça, M. V., Wu, M., Li, C., Li, X., Duman, R. S., & Picciotto, M. R. (2023) · Neuropsychopharmacology · doi:10.1038/s41386-023-01583-7 · Cited by 28
Stress-Induced Deficits in Cognition and Emotionality: A Role for Glutamate
Graybeal, C., Kiselycznyk, C., & Holmes, A. (2011) · Current topics in behavioral neurosciences · doi:10.1007/7854_2011_193 · Cited by 30
N-methyl-d-aspartic acid receptors are altered by stress and alcohol in Wistar–Kyoto rat brain
Lei, Y., & Tejani‐Butt, S. M. (2010) · Neuroscience · doi:10.1016/j.neuroscience.2010.05.003 · Cited by 29
Borsoï, M., Antonio, C. B., Müller, L. G., Viana, A. F., Hertzfeldt, V., Lunardi, P. S., Zanotto, C., Nardin, P., Ravazzolo, A. P., Rates, S. M. K., et al. (2014) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2014.11.012 · Cited by 27
Srivastava, A., Singh, P., Gupta, H., Kaur, H., Kanojia, N., Guin, D., Sood, M., Chadda, R. K., Yadav, J., Vohora, D., et al. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20081993 · Cited by 26
Nghia, N. A., Hirasawa, T., Kasai, H., Obata, C., Moriishi, K., Mochizuki, K., Koizumi, S., & Kubota, T. (2015) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2015.02.010 · Cited by 26
Metadata
- Authors
- Feyissa, A. M., Chandran, A., Stockmeier, C. A., & Karolewicz, B.
- Affiliations
- University of Mississippi Medical Center (US)
- Corresponding author
- Karolewicz, Beata
- Venue
- Progress in Neuro-Psychopharmacology and Biological Psychiatry
- Publisher
- Elsevier BV
- Published
- 2009-02
- Volume
- 33
- Issue
- 1
- Pages
- 70-75
- ISSN
- 0278-5846 (ISSN-L)
- PMC
- PMC2655629
- OpenAlex
- W2054535395
- Cited by
- 421
- References
- 46
- Citations by year
- 2026: 19 · 2025: 21 · 2024: 29 · 2023: 28 · 2022: 31 · 2021: 34 · 2020: 34 · 2019: 25 · 2018: 25 · 2017: 14 · 2016: 27 · 2015: 28 · 2014: 24 · 2013: 21 · 2012: 15
- FWCI
- 10.75
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Progress in Neuro-Psychopharmacology and Biological Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health (5p20rr017701-10)
- National Institute of Mental Health (R01MH067996, MH67996)
- National Center for Research Resources (P20-RR-017701, RR 17701)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Keywords
- major depressive disorder, NMDA receptor, NR2A, NR2B, NR1 subunit, PSD-95, prefrontal cortex, glutamatergic neurotransmission, postmortem brain, antidepressant targets, glutamatergic dysfunction
- MeSH terms
- Disks Large Homolog 4 Protein, Adult, Carrier Proteins, Major Depressive Disorder, Female, Humans, Male, Membrane Proteins, Middle Aged, Nerve Tissue Proteins, Signal Transduction, Receptors, N-Methyl-D-Aspartate, Prefrontal Cortex, Intracellular Signaling Peptides and Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review